PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Ghrelin is a prognostic marker and a potential therapeutic target in breast cancer.

Abstract Ghrelin and obestatin are gastrointestinal peptides, encoded by the same preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has been implicated in breast cancer tumorigenesis. Despite recent advances in breast cancer management the need for new prognostic markers and potential therapeutic targets in breast cancer remains high. We studied the prognostic impact of ghrelin and obestatin in women with node negative breast cancer. Within a cohort of women with breast cancer with tumor size ≤ 50 mm, no lymph node metastases and no initiation of adjuvant chemotherapy, 190 women were identified who died from breast cancer and randomly selected 190 women alive at the corresponding time as controls. Tumor tissues were immunostained with antibodies versus the peptides. Ghrelin expression was associated with better breast cancer specific survival in univariate analyses (OR 0.55, 95% CI 0.36-0.84) and in multivariate models, adjusted for endocrine treatment and age (OR 0.57, 95% CI 0.36-0.89). Obestatin expression was non-informative (OR 1.2, 95% CI 0.60-2.46). Ghrelin expression is independent prognostic factor for breast cancer death in node negative patients-halving the risk for dying of breast cancer. Our data implies that ghrelin could be a potential therapeutic target in breast cancer treatment.
PMID
Related Publications

Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study.

Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.

Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer.

Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort.

Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.

Authors

Mayor MeshTerms
Keywords
Journal Title plos one
Publication Year Start




PMID- 28419141
OWN - NLM
STAT- In-Process
DA  - 20170418
LR  - 20170418
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 12
IP  - 4
DP  - 2017
TI  - Ghrelin is a prognostic marker and a potential therapeutic target in breast
      cancer.
PG  - e0176059
LID - 10.1371/journal.pone.0176059 [doi]
AB  - Ghrelin and obestatin are gastrointestinal peptides, encoded by the same
      preproghrelin gene. Both are expressed in breast cancer tissue and ghrelin has
      been implicated in breast cancer tumorigenesis. Despite recent advances in breast
      cancer management the need for new prognostic markers and potential therapeutic
      targets in breast cancer remains high. We studied the prognostic impact of
      ghrelin and obestatin in women with node negative breast cancer. Within a cohort 
      of women with breast cancer with tumor size </= 50 mm, no lymph node metastases
      and no initiation of adjuvant chemotherapy, 190 women were identified who died
      from breast cancer and randomly selected 190 women alive at the corresponding
      time as controls. Tumor tissues were immunostained with antibodies versus the
      peptides. Ghrelin expression was associated with better breast cancer specific
      survival in univariate analyses (OR 0.55, 95% CI 0.36-0.84) and in multivariate
      models, adjusted for endocrine treatment and age (OR 0.57, 95% CI 0.36-0.89).
      Obestatin expression was non-informative (OR 1.2, 95% CI 0.60-2.46). Ghrelin
      expression is independent prognostic factor for breast cancer death in node
      negative patients-halving the risk for dying of breast cancer. Our data implies
      that ghrelin could be a potential therapeutic target in breast cancer treatment.
FAU - Gronberg, Malin
AU  - Gronberg M
AUID- ORCID: http://orcid.org/0000-0003-4001-0572
AD  - Department of Medical Sciences, Section of Endocrine Oncology, Uppsala
      University, Uppsala, Sweden.
FAU - Ahlin, Cecilia
AU  - Ahlin C
AD  - Department of Oncology, Faculty of Medicine and Health, Orebro University,
      Orebro, Sweden.
FAU - Naeser, Ylva
AU  - Naeser Y
AD  - Department of Medical Sciences, Section of Endocrine Oncology, Uppsala
      University, Uppsala, Sweden.
FAU - Janson, Eva Tiensuu
AU  - Janson ET
AD  - Department of Medical Sciences, Section of Endocrine Oncology, Uppsala
      University, Uppsala, Sweden.
FAU - Holmberg, Lars
AU  - Holmberg L
AD  - Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
AD  - Faculty of Life Sciences and Medicine, King's College London, London, United
      Kingdom.
FAU - Fjallskog, Marie-Louise
AU  - Fjallskog ML
AD  - Department of Medical Sciences, Section of Endocrine Oncology, Uppsala
      University, Uppsala, Sweden.
LA  - eng
PT  - Journal Article
DEP - 20170418
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
EDAT- 2017/04/19 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/04/19 06:00
PHST- 2017/01/27 [received]
PHST- 2017/04/04 [accepted]
AID - 10.1371/journal.pone.0176059 [doi]
AID - PONE-D-17-03630 [pii]
PST - epublish
SO  - PLoS One. 2017 Apr 18;12(4):e0176059. doi: 10.1371/journal.pone.0176059.
      eCollection 2017.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>